What's Happening?
The French CombinaiR3 phase II trial has investigated a sequential multimodal approach for treating newly diagnosed patients with multimetastatic Ewing sarcoma. The trial enrolled 45 very high-risk patients across
15 French centers from 2017 to 2021, focusing on a strategy that combines dose-dense induction chemotherapy, high-dose consolidation, and prolonged maintenance therapy. The primary endpoint was median event-free survival, with exploratory endpoints including PET/CT and circulating tumor DNA detection during treatment.
Why It's Important?
This study provides valuable insights into potential first-line treatment options for very high-risk Ewing sarcoma patients, a group characterized by poor overall survival rates. The findings could influence international therapeutic discussions and lead to improved treatment protocols for this aggressive cancer. The correlation between PET/CT and ctDNA monitoring at diagnosis and relapse offers promising avenues for more precise and personalized treatment strategies, potentially improving patient outcomes.
